What is 'Alzheimer's disease'? The neuropathological heterogeneity of clinically defined Alzheimer's dementia
- PMID: 33591030
- DOI: 10.1097/WCO.0000000000000912
What is 'Alzheimer's disease'? The neuropathological heterogeneity of clinically defined Alzheimer's dementia
Abstract
Purpose of review: Beta-amyloid with paired helical filaments (PHF)-tau neurofibrillary tangles define hallmark Alzheimer's disease neuropathologic changes (AD-NC). Yet persons with Alzheimer's dementia, defined broadly as an amnestic multidomain progressive dementia, often exhibit postmortem evidence of other neuropathologies including other neurodegenerative (Lewy body disease and transactive response DNA-binding protein disease) and vascular-related brain lesions. Clinicopathologic and epidemiologic analyses demonstrate the significance of these substrates, as coinciding neuropathologies mitigate the threshold for diagnosis of Alzheimer's dementia. In addition, other biologic processes may also independently underlie a progressive amnestic dementia. Advances in research on the relationship between age-related cognitive decline and the underlying neuropathologic substrates indicate that consensus neuropathologic criteria or disease nomenclature may need new considerations or refinement. This review appraises seminal literature as well as mixed pathologies and biological factors that may be determinants of clinical and pathologic disease.
Recent findings: Cognition in aging (spanning from normal cognition to dementia) represents a clinical continuum. Traditional neuropathologic substrates of dementia however do not explain the variability of cognitive decline. Conversely, not all patients with AD-NC exhibit symptomatology of Alzheimer's dementia. In addition to diagnostic plaques and tangles, other neurodegenerative, cerebrovascular, and perivascular substrates manifest through discrete tissue lesions. Factors related to energetics, neurogenetics, neuroimmunology, resilience, proteinopathies, and waste clearance are increasingly suggested to be general drivers of disease. Recognition of novel neuroimmune pathways and brain-body connections further suggest there may be broader extracranial determinants of person-specific disease.
Summary: Alzheimer's dementia is a pathologically heterogeneous and biologically multilayered disease. Recent studies and exercises in nomenclature reveal shortcomings in existing terminologies. Recognizing and overcoming these limitations is required for experts to effectively communicate about and ultimately prevent and treat Alzheimer's dementia.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
The neuropathological diagnosis of Alzheimer's disease.Mol Neurodegener. 2019 Aug 2;14(1):32. doi: 10.1186/s13024-019-0333-5. Mol Neurodegener. 2019. PMID: 31375134 Free PMC article. Review.
-
Multiple gene variants linked to Alzheimer's-type clinical dementia via GWAS are also associated with non-Alzheimer's neuropathologic entities.Neurobiol Dis. 2022 Nov;174:105880. doi: 10.1016/j.nbd.2022.105880. Epub 2022 Sep 30. Neurobiol Dis. 2022. PMID: 36191742 Free PMC article.
-
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.Arch Neurol. 1998 Mar;55(3):326-35. doi: 10.1001/archneur.55.3.326. Arch Neurol. 1998. PMID: 9520006
-
The Vascular-Immune Hypothesis of Alzheimer's Disease.Biomedicines. 2023 Jan 30;11(2):408. doi: 10.3390/biomedicines11020408. Biomedicines. 2023. PMID: 36830944 Free PMC article. Review.
-
[Neuropathologic Aspects of Co-occurrence of Dementia with Lewy Bodies and Alzheimer's Disease].Brain Nerve. 2018 Aug;70(8):905-913. doi: 10.11477/mf.1416201099. Brain Nerve. 2018. PMID: 30082500 Review. Japanese.
Cited by
-
Influence of Alzheimer's disease related neuropathology on local microenvironment gene expression in the human inferior temporal cortex.GEN Biotechnol. 2023 Oct;2(5):399-417. doi: 10.1089/genbio.2023.0019. Epub 2023 Oct 16. GEN Biotechnol. 2023. PMID: 39329069 Free PMC article.
-
Exploring the Role of Glycolytic Enzymes PFKFB3 and GAPDH in the Modulation of Aβ and Neurodegeneration and Their Potential of Therapeutic Targets in Alzheimer's Disease.Appl Biochem Biotechnol. 2023 Jul;195(7):4673-4688. doi: 10.1007/s12010-023-04340-0. Epub 2023 Jan 24. Appl Biochem Biotechnol. 2023. PMID: 36692648 Review.
-
Accelerating Alzheimer's therapeutic development: The past and future of clinical trials.Cell. 2023 Oct 26;186(22):4757-4772. doi: 10.1016/j.cell.2023.09.023. Epub 2023 Oct 16. Cell. 2023. PMID: 37848035 Free PMC article. Review.
-
Temporal Changes in Alzheimer's Disease-Related Biomarkers in the CSF of Cognitively Normal Subjects at Different Ages: The Chongqing Ageing and Dementia Study.Aging Cell. 2025 Jun;24(6):e70036. doi: 10.1111/acel.70036. Epub 2025 Mar 9. Aging Cell. 2025. PMID: 40057942 Free PMC article.
-
Review of Associations of Diabetes and Insulin Resistance With Brain Health in Three Harmonised Cohort Studies of Ageing and Dementia.Diabetes Metab Res Rev. 2025 Jan;41(1):e70032. doi: 10.1002/dmrr.70032. Diabetes Metab Res Rev. 2025. PMID: 39873127 Free PMC article. Review.
References
-
- Alzheimer's Association. 2020 Alzheimer's disease facts and figures. Alzheimers Dement 2020; 16:391–460.
-
- Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8:1–13.
-
- Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997; 56:321–339.
-
- Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience 2001; 105:99–107.
-
- Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014; 128:755–766.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials